Author

Michael S Epstein 1

1 Investigative Clinical Research,A

A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2

Vipul Jairath, Reena Khanna, Leonard Guizzetti, Guangyong Zou, Joan Morris, Lisa Shackelton, Parambir Dulai, Humberto Aguilar, Oliver Brain, Matthew Brookes, Aminda De Silva, Michael S Epstein, Baroudi Fashir, John N. Gordon, William Harlan III, Ulf Helwig, Caroline Hwang, Pierre Laflamme, Rebecca Matro, Mark C. Mattar;;

CORRELATION OF BIOMARKERS OF INFLAMMATION WITH CLINICAL AND ENDOSCOPIC ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: DATA FROM CELEST

Jean-Frederic Colombel, Laurent Peyrin-Biroulet, Silvio Danese, Simon Travis, Gerald Dryden, Robert Hardi, Michael S Epstein, Wen Zhou, Fabio Cataldi, Bidan Huang, Ana Paula Lacerda, Julian Panés

EFFICACY AND SAFETY OF THE NOVEL 1L PEG AND ASCORBATE BOWEL PREPARATION NER1006 VERSUS TRISULFATE SOLUTION IN OVERNIGHT SPLIT-DOSING ADMINISTRATION: RESULTS FROM THE PHASE 3 STUDY NOCT

Michael DeMicco, Lucy B Clayton, Richard Ng Kwet Shing, Michael S Epstein

GASTROINTESTINAL SAFETY OF LONG-TERM PEG-J USED FOR CONTINUOUS INFUSION OF LEVODOPA-CARBIDOPA INTESTINAL GEL

Michael S Epstein, David Johnson, Robert Hawes, Nathan Schmulewitz, Arvydas Vanagunas, Rod Gossen, Susan Eaton, Jordan Dubow, Krai Chatamra, Weining Z Robieson, Janet Benesh

HIGH-QUALITY CLEANSING IMPROVES LESION DETECTION DURING COLONOSCOPY COMPARED TO ADEQUATE CLEANSING: POST HOC ANALYSIS OF 1170 CENTRAL-READER ASSESSED PATIENTS IN THREE RANDOMISED PHASE 3 TRIALS

Cesare Hassan, Jonathan Manning, Juha Halonen, Bharat Amlani, Michael S Epstein

HIGHER HAREFIELD CLEANSING SCALE SCORES ARE ASSOCIATED WITH IMPROVED LESION DETECTION: POST HOC ANALYSIS OF THREE RANDOMISED AND CENTRAL READER-ASSESSED PHASE 3 CLINICAL TRIALS

Jonathan Manning, Cesare Hassan, Juha Halonen, Bharat Amlani, Michael S Epstein

PHASE III RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADD-ON FIXED-DOSE ANTI-MYCOBACTERIAL THERAPY (RHB-104) IN MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (MAP US)

David Y. Graham, Robert Hardi, Thomas Welton, Richard Krause, Scott Levenson, Harry Sarles, Aasim Sheikh, Michael S Epstein, George Duvall, Curtis Freedland, Zbigniew Hebzda, Tomasz Arlukowicz, Adam Kopon, Grzyna Rydzewska, Natasa Zdravkovic, Peter Svorcan, Eran Zittan, Predrag Dugalic, Eran Israeli, Patricia Anderson,

Item 1 - 7 / 7
1